IGC Pharma, Inc. IGC

IGC Pharma reported Q2 2026 results as its CALMA Alzheimer's trial reached within six randomizations of enrollment closure. Nearing CALMA trial enrollment closure advances IGC's core Alzheimer's program and can materially shift future prospects and investor views.

IGC Pharma advances regulatory preparations as Phase 2 CALMA Alzheimer's trial nears enrollment closure with Q4 topline readout expected. Trial enrollment closure and upcoming topline data can materially shift company trajectory and investor sentiment.

IGC Pharma evaluates recovery options after federal jury verdict revives attention on 2018 short campaign. Jury verdict revives past short campaign scrutiny likely causing temporary market sentiment shifts.

IGC Pharma's AHA Agentic AI Platform cuts Alzheimer's data harmonization time by 90% in representative workflow. AI platform efficiency gain advances IGC's core Alzheimer's research capabilities and competitive edge.

IGC Pharma reached its previously disclosed 146-patient enrollment target in the Phase 2 CALMA Trial and is advancing toward topline analysis. Reaching Phase 2 enrollment target advances clinical development timeline and may affect near-term sentiment but does not alter long-term trajectory until data readout.

Ascendiant Capital Markets raised IGC Pharma price target to $5.50 citing clinical progress and 2026 catalysts. Analyst price target upgrade to $5.50 signals positive sentiment on clinical pipeline.

IGC Pharma adds Mount Sinai as a clinical site for the CALMA trial, moving the study toward completion and topline analysis. Mount Sinai site addition advances CALMA trial toward completion and topline data release.

IGC Pharma reported first quarter 2026 financial results. CALMA Phase 2 trial reached final stage at 80% enrollment. CALMA Phase 2 reaching final stage at 80% enrollment points to near-term clinical milestones that can shift company trajectory.

IGC Pharma advances caregiver engagement initiatives as its Phase 2 CALMA trial for Alzheimer's agitation enters final enrollment phase. Phase 2 trial reaching final enrollment signals moderate pipeline progress, potentially lifting sentiment but limited until data readout.

IGC Pharma adds Kerwin Medical Center in Dallas to its Phase 2 CALMA trial as enrollment advances toward completion. Adding a new clinical trial site and nearing enrollment completion moderately advances IGC's Phase 2 CALMA study pipeline.

IGC Pharma, Inc. (IGC) secures psilocybin research authorization, expanding its focus on neuropsychiatric symptoms in dementia. Psilocybin research authorization enables major strategic expansion into dementia neuropsychiatric treatments, significantly boosting pipeline potential and investor sentiment.

IGC Pharma, Inc. (IGC) reached 80% enrollment in its Phase 2 CALMA Trial, entering the final phase ahead of full enrollment completion and data readout. Achieving 80% enrollment in Phase 2 CALMA Trial advances IGC toward critical data readout, likely enhancing investor sentiment and market performance.

Ascendiant Capital Markets raises IGC Pharma (IGC) price target to $5.25, citing clinical progress and upcoming catalysts. Analyst price target hike to $5.25 highlights clinical advancements and catalysts, poised to significantly boost investor sentiment and stock trajectory.

IGC Pharma, Inc. (IGC) adds Tandem Clinical Research to the CALMA Trial targeting agitation in Alzheimer's Disease. Adding a clinical research site to the CALMA Trial advances IGC's pipeline progress in Alzheimer's agitation treatment.

IGC Pharma, Inc. (IGC) reported financial results and clinical progress for the period ended December 31, 2025. Financial results combined with clinical progress represent major updates on operational health and pipeline advancement, likely to significantly sway investor sentiment and stock trajectory.

IGC Pharma will showcase its AI platform, featuring the Alzheimer's Disease Data Initiative, at the ADPD 2026 conference. Showcasing AI-driven Alzheimer's initiative at ADPD 2026 boosts visibility and competitive positioning without transformative near-term outcomes.

IGC Pharma, Inc. (IGC) filed utility patent applications for an AI-based data harmonization architecture designed to support Alzheimer's research. Patent applications for AI-driven Alzheimer's research tools bolster IGC's innovation in neurodegenerative diseases with moderate potential to influence competitive positioning.

IGC Pharma, Inc. (IGC) expanded its Phase 2 CALMA trial by adding a new clinical site to accelerate patient enrollment and advance Alzheimer's disease treatment development. Expanding a Phase 2 trial with a new site moderately boosts pipeline progress and investor sentiment without fundamentally altering long-term prospects.

IGC Pharma, Inc. (IGC) added Visionary Investigators Network as a clinical site for its Phase 2 CALMA trial targeting agitation in Alzheimer's disease. Adding a new clinical site to the Phase 2 CALMA trial accelerates enrollment and supports pipeline progress with moderate impact on investor sentiment and development timeline.

IGC Pharma secures North American composition-of-matter protection for its Alzheimer's disease drug candidate IGC-AD1 while advancing patient enrollment in the Phase 2 CALMA clinical trial. IP protection for IGC-AD1 and Phase 2 enrollment progress represent major advancements in IGC's Alzheimer's pipeline, enhancing competitive positioning and investor appeal.

IGC Pharma, Inc. (IGC) has received an equity research update from Alliance Global Partners, highlighting the company's recent developments and future prospects. The update emphasizes IGC's strategic initiatives and market positioning, which may influence investor sentiment and market performance. The equity research update may moderately influence investor sentiment and market performance but is not expected to fundamentally alter the company's trajectory.

IGC Pharma, Inc. has expanded its Phase 2 CALMA trial into Colombia's leading Alzheimer's research center, aiming to enhance its clinical research capabilities and patient recruitment for the study. This expansion is part of IGC's strategy to advance its investigational product, which targets Alzheimer's disease, and to leverage Colombia's expertise in neurological research. Expanding the CALMA trial into a premier research center is likely to significantly enhance IGC's clinical development and market positioning in Alzheimer's treatment.

IGC Pharma, Inc. has achieved 70% enrollment in its Phase 2 CALMA trial, which is evaluating IGC-AD1 for treating agitation associated with Alzheimer's disease. The trial aims to assess the efficacy and safety of IGC-AD1, a cannabinoid-based treatment, in addressing this challenging symptom of Alzheimer's. The company is optimistic about the trial's progress and its potential implications for patients suffering from Alzheimer's agitation. The advancement in the CALMA trial represents a significant step in IGC's product development and could influence its market position and investor sentiment.

IGC Pharma, Inc. has expanded its Phase 2 CALMA trial by adding a new clinical trial site at Integrative Clinical Trials in New York. This expansion aims to enhance the study's reach and effectiveness in evaluating the company's therapeutic approach. The addition of a new clinical trial site may moderately influence IGC's operational capabilities and market perception.

IGC Pharma, Inc. has expanded its Phase 2 CALMA trial by adding a new clinical site at Dominion Medical Associates in Richmond, Virginia, which is part of the Lightship Network. This expansion aims to enhance patient recruitment and accelerate the trial's progress. The addition of a new clinical site may moderately influence patient recruitment and trial outcomes, impacting the company's operational performance.

IGC Pharma, Inc. has announced a strategic decision to align its fiscal year with the calendar year. This change aims to enhance transparency and comparability for U.S. investors, potentially improving the company's appeal in the market. The adjustment is expected to streamline financial reporting and provide clearer insights into the company's performance. Aligning the fiscal year with the calendar year may improve investor transparency and comparability, positively influencing market sentiment.

IGC Pharma, Inc. has successfully raised capital to support the advancement of its IGC-AD1 Phase 2 clinical trial. This funding is aimed at furthering the development of the company's cannabinoid-based treatment for Alzheimer's disease, which is currently in the testing phase. The capital raise is expected to enhance the company's research capabilities and accelerate the trial process, potentially leading to significant advancements in treatment options for Alzheimer's patients. The capital raised is crucial for advancing a key clinical trial that could significantly impact the company's future and market position.

IGC Pharma, Inc. has secured a new U.S. patent for its pharmaceutical cannabinoid formulations, which is expected to enhance its product offerings and align with the growing regulatory acceptance of cannabinoid-based therapies. This patent is part of IGC's strategy to capitalize on the expanding market for cannabinoid pharmaceuticals, potentially positioning the company for increased growth and innovation in the sector. The new patent is likely to significantly enhance IGC's competitive position and market opportunities in the evolving pharmaceutical cannabinoid landscape.

IGC Pharma, Inc. is positioned to benefit from the increasing federal momentum towards Schedule III cannabinoid medicines. The company is strategically aligning itself to capitalize on potential regulatory changes that could enhance its market position and product offerings in the cannabinoid sector. This shift in federal policy may open new avenues for growth and innovation within the industry, positioning IGC as a key player in the evolving landscape of cannabinoid pharmaceuticals. Emerging federal momentum toward Schedule III cannabinoid medicines could significantly alter IGC's market positioning and growth trajectory.

President Trump is expected to sign an executive order on Monday to reclassify marijuana, which could have significant implications for the cannabis industry and companies like IGC Pharma, Inc. (IGC). This move may alter the legal status of marijuana, potentially impacting regulations and market dynamics. Reclassification of marijuana could significantly change regulatory frameworks and market opportunities for IGC Pharma.